Charles Dimmler is a business co-founder, principal investor, and executive chairman of Ceramedix, Inc. A former venture capitalist, operating executive, and life sciences entrepreneur and investor, he has led the company's business strategy since its formation.
Galina Vid is vice president of operations at Ceramedix, Inc. She works with regulatory, research, manufacturing, and business teams to optimize workflows and improve efficiency, and develops strategies to streamline clinical translation of its anti-ceramide technology.
Dr. Julia Busik is chief scientific officer of Ceramedix, Inc. and chief of its Scientific and Medical Advisory Board. She directs scientific strategy and research and has developed anti-ceramide antibodies with Dr. Richard Kolesnick.
Lisa Janicki is controller at Ceramedix, Inc. She oversees financial operations, ensures regulatory compliance, and supports the company's growth and strategic objectives.
Ceramedix, Inc. was founded on research from MSK identifying a ceramide-rich platform as a marker of vascular cell death and damage. It holds an exclusive global license to ceramide-targeting antibodies developed at MSK and MSU.
